Cancer Center Support (CORE) Grant

杰克逊实验室癌症中心（JAXCC）提供了一个独特的集中的遗传和 基因组专业知识，重点是小鼠模型系统和系统基因组学在解决 癌症问题。JAXCC在一个研究项目中有47名成员，即精确遗传模型 癌症医学包括癌细胞稳健性、遗传和基因组复杂性的3个相关主题， 和祖细胞生物学。总的来说，我们寻求确定内在癌症的分子驱动因素， 抵抗、癌症演变、适应和自我更新。在基因组技术方面的创新， 计算分析和人类癌症的小鼠模型是所有主题的组成部分， 跨学科结构。JAXCC现在在3个校区运营：JAX哺乳动物遗传学（巴尔港， ME），专注于复杂遗传学的小鼠模型; JAX基因组医学（法明顿，CT）， 专注于人类癌症基因组学; JAX-West（萨克拉门托，加利福尼亚州）专注于使用 人癌症的患者来源的异种移植物（PDX）小鼠模型。JAX的科学领导层直接 癌症中心的监督：Edison Liu博士是JAX的总裁兼首席执行官，也是JAXCC的主任。博士 Robert Braun是JAX研究副总裁兼癌症中心副主任。卡罗尔博士 Bult、Chengkai Dai和Frank McKeon是联合项目负责人。区域事务协理主任 翻译合作伙伴关系（博士.凯文米尔斯）和研究管理（博士.芭芭拉Tennent）扩大 领导结构。一个专门的7人外部咨询委员会（EAB）为他们提供建议。新 领导能力，同时征聘新的高级和初级调查员， 癌症研究的机构资源加强了JAXCC的影响。这一点已经在 通过区域和国家伙伴关系扩大JAXCC的翻译外联（例如，SWOG）。支持 要求共享资源：a）计算科学，高级计算和统计 B）基因组技术，用于下一代测序和代谢组学方面的创新， 蛋白质组学分析; c）癌症模型开发，用于开发过程中的咨询和项目管理 d）操纵生殖系和体细胞基因表达的遗传工程技术 e）用于显微镜检查、细胞遗传学、临床评估、组织学和免疫学的表型分析技术。 流式细胞仪还要求提供资金，以支助欧洲咨询委员会年度会议和JAXCC成员务虚会。 为一个试点项目申请了发展资金，并得到机构资金的大量补充 该计划旨在刺激新的癌症研究机会，并支持JAXCC的新研究人员。

The Jackson Laboratory Cancer Center (JAXCC) provides a unique concentration of genetic and genomic expertise focusing on applications of murine model systems and systems genomics in addressing cancer questions. The JAXCC has 47 members in one Research Program, Genetic Models for Precision Cancer Medicine comprising 3 related themes in cancer cell robustness, genetic and genomic complexity, and progenitor cell biology. Collectively, we seek to determine the molecular drivers of intrinsic cancer resistance, cancer evolution, adaptation, and self-renewal. Innovations In genomic technologies, computational analytics and mouse models for human cancers are integral to all themes, providing a robust interdisciplinary structure. The JAXCC now operates on 3 campuses: JAX Mammalian Genetics (Bar Harbor, ME) with a focus on mouse models for complex genetics; JAX Genomic Medicine (Farmington, CT), with a focus on human cancer genomics; and JAX-West (Sacramento, CA) with a focus on pre-clinical trials using patient-derived-xenograft (PDX) mouse models of human cancer. The scientific leadership of JAX has direct oversight of the Cancer Center: Dr. Edison Liu is President and CEO of JAX and Director of the JAXCC. Dr. Robert Braun Is Vice President for Research of JAX and Deputy Director of the Cancer Center. Drs. Carol Bult, Chengkai Dai and Frank McKeon are co-Program Leaders. Associate Directors for Regional Translational Partnerships (Dr. Kevin Mills) and Research Administration (Dr. Barbara Tennent) expand the leadership structure. A dedicated 7-member External Advisory Board (EAB) advises them. The new leadership, combined with recruitment of new senior and junior investigators, and a significant increase in institutional resources for cancer research heightens the impact of the JAXCC. This has been realized In the expanded JAXCC translational outreach through regional and national partnerships (e.g., SWOG). Support is requested for Shared Resources: a) Computational Sciences, for advanced computational and statistical analysis; b) Genome Technologies, for innovations in next generation sequencing, and in metabolomic and proteomic analyses; c) Cancer Model Development for consultation and project management in developing new models; d) Genetic Engineering Technologies for manipulating germline and somatic gene expression in mice; and e) Phenotyping Technologies for microscopy, cytogenetics, clinical assessment, histology and flow cytometry. Funds are also requested for support of annual EAB meetings and JAXCC member retreats. Developmental funds significantly supplemented by institutional funds are requested for a pilot project program to stimulate new cancer research opportunities and for support of new investigators to the JAXCC.